Cytokinetics receives FDA orphan drug status for Ck-2127107 to treat SMA

Biopharmaceutical company Cytokinetics ’ CK-2127107 has received orphan drug designation from the Office of Orphan Products Development of the US Food and Drug Administration (FDA) for the potential treatment of spinal muscular atrophy (SMA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news